Development of an Innovative Effective RNA based Vaccine for Chikungunya Virus

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43AI127053-01A1
Agency Tracking Number: R43AI127053
Amount: $224,998.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIAID
Solicitation Number: PA16-302
Timeline
Solicitation Year: 2016
Award Year: 2017
Award Start Date (Proposal Award Date): 2017-03-15
Award End Date (Contract End Date): 2018-11-30
Small Business Information
1616 EASTLAKE AVE E STE 550, Seattle, WA, 98102-3788
DUNS: 148051621
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 NEAL VANHOEVEN
 (206) 858-6014
 neal.vanhoeven@idri.org
Business Contact
 DARRICK CARTER
Phone: (206) 623-0331
Email: darrick.carter@pailifesciences.com
Research Institution
N/A
Abstract
PROJECT SUMMARY ABSTRACT Chikungunya virus CHIKV is an emerging disease of global public health importance Originally identified in sporadic CHIKV outbreaks occurred in Africa and Asia for several decades Beginning with an outbreak on the island of La Reunion in the virus has continued to spread to new regions around the globe CHIKV is now endemic in the Caribbean is present in the Americas and continues to cause devastating outbreaks in India and Southeast Asia Chikungunya vaccine development began with the generation of both traditional inactivated whole virus vaccines as well as live attenuated candidates Additional advancement came in the development of viral vectored and subunit vaccines Recently two candidate vaccines have progressed into Phase and Phase clinical testing However until these vaccines are proven additional candidates are sorely needed The recent development of vector independent RNA based delivery systems represents an attractive platform for rapid and inexpensive development of new vaccine candidates RNA based antigen delivery candidates may be generated and purified using a common fully synthetic process which alleviates the need for time consuming antigen specific process development Central to the utility of this platform is the development of an effective RNA delivery formulation capable of promoting in vivo expression of antigen proteins from vaccine candidates following injection This phase I SBIR proposal will utilize a proprietary and compositionally unique RNA delivery formulation to develop novel RNA based CHIKV vaccine candidates Following generation of vaccine candidate RNA we will verify viral protein expression and quantify secreted virus like particles in vitro In addition we will verify that RNA vaccines do not generate replicating virus relative to a full length CHIKV genome control by titration of transfection supernatants Candidates shown to generate viral proteins in the absence of replication competent virus will be advanced into immunogenicity studies in mice Comprehensive analysis of the immune response including the induction of CHIKV neutralizing antibody will confirm potency of RNA vaccine Following down selection to two lead candidate RNA vaccines we will carry out efficacy testing in multiple mouse challenge models The results of these challenge studies will define two novel CHIKV vaccine candidates which will then be advanced into cGMP manufacturing toxicology and clinical testing in a subsequent SBIR Phase II proposal PROJECT NARRATIVE Chikungunya virus CHIKV is an emerging disease of global public health importance which can cause debilitating long term morbidity most notably severe arthritis in many of those infected Vaccine development for CHIKV began in the andapos s and while a number of promising vaccine candidates have been clinically tested issues with vaccine safety manufacturing and pre existing vector immunity exist which may limit their utility This proposal will develop a novel safe and effective CHIKV vaccine by formulating new RNA based vaccine candidates with a proprietary RNA delivery formulation and will demonstrate immunogenicity and efficacy of two lead candidate CHIKV vaccines in multiple animal models of disease

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government